Breaking News Instant updates and real-time market news.

2020-03-30 06:08:43 BSGM BioSig Technologies $5.15 / -0.89 (-14.74%) 06:08 03/30/20 03/30 06:08 03/30/20 06:08	BioSig Technologies initiated with a Buy at Roth Capital Roth Capital analyst Scott Henry initiated coverage of BioSig Technologies with a Buy rating and $9 price target. The company will successfully launch the PURE EP system into the "large and rapidly-growing" electrophysiology market, Henry tells investors in a research note. The analyst says PURE EP appears to be a superior signal processor.

2020-03-30 06:08:43

BSGM

BioSig Technologies

$5.15 / -0.89 (-14.74%)

06:08

03/30/20

03/30

06:08

03/30/20

06:08

BioSig Technologies initiated with a Buy at Roth Capital

Roth Capital analyst Scott Henry initiated coverage of BioSig Technologies with a Buy rating and $9 price target. The company will successfully launch the PURE EP system into the "large and rapidly-growing" electrophysiology market, Henry tells investors in a research note. The analyst says PURE EP appears to be a superior signal processor.

OTHER BREAKING NEWS FROM THE FLY

Downgrade	Momentive downgraded to Hold from Buy at Truist » 13:33 03/27/23 03/27 13:33 03/27/23 13:33 MNTV Momentive $9.29 / +0.02 (+0.22%) Truist analyst Youssef… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options MNTV Momentive $9.29 / +0.02 (+0.22%) 03/13/23 Momentive Global trading resumes 03/13/23 Momentive to be acquired by Symphony Technology Group for $1.5B in cash 03/13/23 Momentive Global trading halted, news pending 02/16/23 Momentive announces workforce reduction of 14% MNTV Momentive $9.29 / +0.02 (+0.22%) 03/14/23 Wells Fargo Momentive downgraded to Equal Weight from Overweight at Wells Fargo 03/14/23 Craig-Hallum Momentive downgraded to Hold from Buy at Craig-Hallum 03/14/23 Needham Momentive downgraded to Hold from Buy at Needham 08/22/22 Wells Fargo Momentive price target lowered to $15 from $20 at Wells Fargo MNTV Momentive $9.29 / +0.02 (+0.22%) 02/16/23 Momentive sees Q1 revenue flat to up 2%, consensus $124.2M 02/16/23 Momentive reports Q4 adjusted EPS 14c, consensus 10c 11/03/22 Momentive sees Q4 revenue $120M-$122M, consensus $124.2M 11/03/22 Momentive reports Q3 EPS 4c, consensus 4c MNTV Momentive $9.29 / +0.02 (+0.22%) 03/14/23 What You Missed On Wall Street On Tuesday 03/14/23 What You Missed On Wall Street This Morning 03/14/23 Fly Intel: Pre-market Movers MNTV Momentive $9.29 / +0.02 (+0.22%) 03/14/23 Unusually active option classes on open March 14th 01/03/23 Momentive Global call volume above normal and directionally bullish 11/03/22 Momentive Global options imply 9.8% move in share price post-earnings 10/24/22 Momentive Global put volume heavy and directionally bearish
General news	Treasury's $42 B 2-year note auction was very poor » 13:25 03/27/23 03/27 13:25 03/27/23 13:25 $ECON Economic Data / + Treasury's $42 B… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Periodicals On The Fly Technical Analysis $ECON Economic Data / + 03/22/23 Senators Scott, Warren unveil bipartisan Fed oversight legislation 03/01/23 Einhorn says investors should be 'bearish on stocks and bullish on inflation' $ECON Economic Data / + $ECON Economic Data / + 03/08/23 Biden to propose 25% billionaire tax, Bloomberg says 03/08/23 Biden to propose 25% billionaire tax, Bloomberg says 03/07/23 Powell tells Congress data from January partly reversed softening trends 01/30/23 Fed likely to raise funds rate benchmark by quarter percentage point, WSJ says $ECON Economic Data / + 03/22/23 What You Missed On Wall Street On Wednesday 03/21/23 What You Missed On Wall Street On Tuesday 03/21/23 What You Missed On Wall Street This Morning 03/08/23 What You Missed On Wall Street On Wednesday $ECON Economic Data / + 03/22/23 Fed says 'additional policy firming may be appropriate'
Conference/Events	Oppenheimer emerging biotech analyst to hold analyst/industry conference call » 13:25 03/27/23 03/27 13:25 03/27/23 13:25 RLAY Relay Therapeutics $15.62 / +0.29 (+1.89%) , ARVN Arvinas $26.77 / +0.37 (+1.40%) , OLMA Olema Oncology $3.64 / +0.1 (+2.82%) , AMAM Ambrx Biopharma $9.18 / -0.15 (-1.61%) , GILD Gilead $80.14 / +0.12 (+0.15%) , AZN AstraZeneca $68.93 / +1.01 (+1.49%) , LLY Eli Lilly $334.19 / -1.865 (-0.55%) Biotechnology Analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options ARVN OLMA AMAM GILD AZN LLY ARVN Arvinas $26.77 / +0.37 (+1.40%) 02/23/23 Arvinas expects cash to fund requirements into 2026 12/16/22 Arvinas appoints Everett Cunningham to board of directors 11/22/22 Arvinas says ARV-471 achieves clinical benefit rate of 38% in evaluable patients 11/08/22 Arvinas expects cash to fund operations multiple years beyond 2024 OLMA Olema Oncology $3.64 / +0.1 (+2.82%) 12/07/22 Olema announces results from Phase 1b dose escalation study of OP-125 10/26/22 Olema Oncology announces preliminary results from OP-1250 trial AMAM Ambrx Biopharma $9.18 / -0.15 (-1.61%) 03/07/23 Ambrx Biopharma falls -26.7% 03/07/23 Ambrx Biopharma falls -13.4% 03/07/23 Ambrx Biopharma falls -10.9% 03/06/23 Ambrx Biopharma trading resumes GILD Gilead $80.14 / +0.12 (+0.15%) 03/23/23 Gilead, Pionyr Immunotherapeutics change 2020 exclusive option agreements 03/21/23 Kite announces primary OS analysis results of Phase 3 ZUMA-7 study 03/20/23 Gilead exercises option to license Nurix's NX-0479 03/20/23 Gilead exercises option to exclusively license NX-0479 from Nurix Therapeutics AZN AstraZeneca $68.93 / +1.01 (+1.49%) 05:18 Today Ionis Pharmaceuticals announces NEURO-TTRansform study met co-primary endpoints 03/23/23 AstraZeneca says Calquence conditionally approved in China for first indication 03/09/23 AstraZeneca announces ADAURA trial meets secondary endpoint 03/09/23 AstraZeneca announces AEGEAN trial demonstrated statistical significance LLY Eli Lilly $334.19 / -1.865 (-0.55%) 03/22/23 Roche to collaborate with Lilly on early diagnosis of Alzheimer's disease 03/14/23 Veru says terminating Phase 3 VERACITY trial of sabizabulin 03/08/23 Eli Lilly says primary, secondary endpoints not met in A4 Study 03/08/23 Eli Lilly: FDA accepts sNDA for Jardiance for children 10 years and older RLAY ARVN OLMA AMAM GILD AZN LLY RLAY Relay Therapeutics $15.62 / +0.29 (+1.89%) 03/09/23 Guggenheim Relay Therapeutics price target lowered to $28 from $45 at Guggenheim 03/07/23 H.C. Wainwright Relay Therapeutics price target raised to $46 from $43 at H.C. Wainwright 02/02/23 Oppenheimer Relay Therapeutics initiated with an Outperform at Oppenheimer 01/19/23 JMP Securities Relay Therapeutics price target lowered to $28 from $38 at JMP Securities ARVN Arvinas $26.77 / +0.37 (+1.40%) 03/18/23 Citi Arvinas price target raised to $77 from $72 at Citi 02/23/23 Capital One Arvinas remains one of the best biotechs to own, says Capital One 01/17/23 Truist Arvinas price target lowered to $65 from $100 at Truist 01/12/23 Capital One Arvinas pullback a buying opportunity, says Capital One OLMA Olema Oncology $3.64 / +0.1 (+2.82%) 03/10/23 H.C. Wainwright Olema Oncology price target raised to $15 from $12 at H.C. Wainwright 02/22/23 Credit Suisse Olema Oncology initiated with an Outperform at Credit Suisse 07/06/22 Canaccord Olema Oncology assumed with a Buy at Canaccord 06/09/22 H.C. Wainwright H.C. Wainwright upgrades Olema to Buy after 'huge positive' in data AMAM Ambrx Biopharma $9.18 / -0.15 (-1.61%) 03/03/23 Baird Ambrx Biopharma price target raised to $11 from $4 at Baird 10/19/22 Baird Ambrx Biopharma price target lowered to $4 from $8 at Baird 09/21/22 Baird Ambrx Biopharma price target lowered to $8 from $16 at Baird 04/07/22 Baird Baird starts Ambrx Biopharma with Outperform, $16 price target GILD Gilead $80.14 / +0.12 (+0.15%) 03/20/23 Oppenheimer Oppenheimer reiterates Outperform on Nurix Therapeutics following Gilead news 03/13/23 Stifel Arcellx initiated with a Buy at Stifel 02/14/23 Mizuho Gilead price target raised to $101 from $88 at Mizuho 02/10/23 Cowen Gilead price target raised to $95 from $90 at Cowen AZN AstraZeneca $68.93 / +1.01 (+1.49%) 03/15/23 Berenberg AstraZeneca price target lowered to 124 GBp from 126 GBp at Berenberg 03/07/23 Guggenheim Guggenheim starts Mineralys at Buy, sees multibillion-dollar potential for ASIs 03/07/23 Evercore ISI Mineralys Therapeutics initiated with an Outperform at Evercore ISI 02/21/23 UBS AstraZeneca price target raised to 11,900 GBp from 10,100 GBp at UBS LLY Eli Lilly $334.19 / -1.865 (-0.55%) 03/22/23 Stifel Stifel argues sympathy trading not a predictor for Viking's pending VK2735 data 03/17/23 Stifel Stifel trims Biogen target, but has more confidence lecanemab 'best-in-class' 03/13/23 Wells Fargo Eli Lilly upgraded to Overweight on recent selloff at Wells Fargo 03/13/23 Wells Fargo Eli Lilly upgraded to Overweight from Equal Weight at Wells Fargo RLAY ARVN OLMA GILD AZN LLY RLAY Relay Therapeutics $15.62 / +0.29 (+1.89%) 11/03/22 Relay Therapeutics reports Q3 EPS (76c), consensus (71c) ARVN Arvinas $26.77 / +0.37 (+1.40%) 02/23/23 Arvinas reports Q4 EPS ($1.56), consensus ($1.22) 11/08/22 Arvinas reports Q3 EPS ($1.24), consensus ($1.13) OLMA Olema Oncology $3.64 / +0.1 (+2.82%) 03/09/23 Olema Oncology reports Q4 EPS (65c), consensus (65c) GILD Gilead $80.14 / +0.12 (+0.15%) 02/02/23 Gilead sees FY23 adjusted EPS $6.60-$7.00, consensus $6.73 02/02/23 Gilead reports Q4 adjusted EPS $1.67, consensus $1.49 02/02/23 Notable companies reporting after market close 12/20/22 Gilead expects Tmunity acquisition to reduce FY23 EPS by 18c-22c AZN AstraZeneca $68.93 / +1.01 (+1.49%) 02/09/23 AstraZeneca sees FY23 core EPS up high single to low double-digit percentage 02/09/23 AstraZeneca reports Q4 core EPS $1.38, consensus $1.35 11/10/22 AstraZeneca raises FY22 core EPS view to high 20s to low 30s percentage 11/10/22 AstraZeneca reports Q3 core EPS $1.67, YTD core EPS $5.28 LLY Eli Lilly $334.19 / -1.865 (-0.55%) 03/09/23 Precision BioSciences reports Q4 EPS (26c), consensus (21c) 02/02/23 Eli Lilly raises FY23 adjusted EPS view to $8.35-$8.55 from $8.10-$8.30 02/02/23 Eli Lilly reports Q4 adjusted EPS $2.09, consensus $1.78 02/01/23 Notable companies reporting before tomorrow's open 13 Sep AZN LLY AZN AstraZeneca $68.93 / +1.01 (+1.49%) 12/09/22 AstraZeneca says Dato-DXd 'continued to demonstrate encouraging responses' 11/10/22 AstraZeneca drops plans to submit COVID-19 vaccine to U.S. FDA, WSJ reports 10/20/22 Drugmakers look to limit Medicare's power to negotiate drug prices, WSJ reports LLY Eli Lilly $334.19 / -1.865 (-0.55%) 03/06/23 New diabetes drugs altering how patients are treated, WSJ reports 12/19/22 Eli Lilly's Mounjaro, Trulicity added to FDA shortage list, STATNews reports 10/20/22 Drugmakers look to limit Medicare's power to negotiate drug prices, WSJ reports 10/11/22 New quality issues found at Eli Lilly drug plant, Reuters reports RLAY ARVN OLMA GILD AZN LLY RLAY Relay Therapeutics $15.62 / +0.29 (+1.89%) 09/30/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations ARVN Arvinas $26.77 / +0.37 (+1.40%) 10/25/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations OLMA Olema Oncology $3.64 / +0.1 (+2.82%) 02/22/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations GILD Gilead $80.14 / +0.12 (+0.15%) 02/02/23 Fly Intel: After-Hours Movers 12/30/22 What You Missed On Wall Street This Morning 12/30/22 Biotech Alert: Searches spiking for these stocks today 12/28/22 What You Missed On Wall Street On Wednesday AZN AstraZeneca $68.93 / +1.01 (+1.49%) 02/09/23 What You Missed On Wall Street This Morning 01/19/23 Biotech Alert: Searches spiking for these stocks today 01/09/23 What You Missed On Wall Street On Monday 01/09/23 What You Missed On Wall Street This Morning LLY Eli Lilly $334.19 / -1.865 (-0.55%) 03/13/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/06/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/24/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/02/23 What You Missed On Wall Street On Thursday 14:00 Today Biotechnology 04/03/23 The Future of Oncology Virtual Symposium 04/27/23 Eli Lilly - LLY 04/28/23 Oncologic Drugs Advisory Committee Virtual Meeting 05/01/23 Eli Lilly & Co. 05/03/23 Gilead Sciences Inc. 05/11/23 Gilead AMAM GILD AZN LLY AMAM Ambrx Biopharma $9.18 / -0.15 (-1.61%) 03/08/23 Ambrx Biopharma call volume above normal and directionally bullish 01/06/23 Largest borrow rate increases among liquid names 12/19/22 Largest borrow rate increases among liquid names 12/15/22 Largest borrow rate increases among liquid names GILD Gilead $80.14 / +0.12 (+0.15%) 02/03/23 Early notable gainers among liquid option names on February 3rd 02/02/23 Gilead options imply 3.5% move in share price post-earnings 11/02/22 Unusually active option classes on open November 2nd 10/28/22 Early notable gainers among liquid option names on October 28th AZN AstraZeneca $68.93 / +1.01 (+1.49%) 11/11/22 AstraZeneca put volume heavy and directionally bearish 11/08/22 AstraZeneca put volume heavy and directionally bearish 10/11/22 AstraZeneca call volume above normal and directionally bullish LLY Eli Lilly $334.19 / -1.865 (-0.55%) 03/13/23 Early notable gainers among liquid option names on March 13th 03/10/23 Early notable gainers among liquid option names on March 10th 11/01/22 Unusually active option classes on open November 1st 10/03/22 Eli Lilly And Co put volume heavy and directionally bearish
Options	Seabridge Gold options imply 2.0% move in share price post-earnings » 13:19 03/27/23 03/27 13:19 03/27/23 13:19 SA Seabridge Gold $12.17 / -0.13 (-1.06%) Pre-earnings options… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research Events Options SA Seabridge Gold $12.17 / -0.13 (-1.06%) 11/21/22 B. Riley Seabridge Gold price target raised to $60 from $57 at B. Riley 10/25/22 B. Riley Seabridge Gold price target lowered to $57 from $105 at B. Riley 04/11/23 Seabridge Gold 04/12/23 Seabridge Gold SA Seabridge Gold $12.17 / -0.13 (-1.06%) 03/20/23 Seabridge Gold options imply 2.0% move in share price post-earnings
Hot Stocks	Air Products announces supply contracts from NASA totaling more than $130M » 13:17 03/27/23 03/27 13:17 03/27/23 13:17 APD Air Products $273.80 / +6.04 (+2.26%) Air Products announced it… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events APD Air Products $273.80 / +6.04 (+2.26%) 03/23/23 Air Products confirms withdrawal from Indonesia coal gasification projects 01/26/23 Air Products increases quarterly dividend by 8% to $1.75 per share 01/20/23 Air Products' joint venture in Saudi Arabia completes second asset transfer 12/08/22 Air Products, AES Corp. to invest $4B in new Texas green hydrogen facility APD Air Products $273.80 / +6.04 (+2.26%) 03/24/23 BMO Capital Air Products price target lowered to $360 from $386 at BMO Capital 03/13/23 Vertical Research Air Products upgraded to Buy from Hold at Vertical Research 03/07/23 Evercore ISI Evercore adds Air Products to 'Tactical Outperform' list, ups target 02/06/23 Morgan Stanley Air Products price target lowered to $315 from $335 at Morgan Stanley APD Air Products $273.80 / +6.04 (+2.26%) 02/02/23 Air Products backs FY23 adjusted EPS view $11.20-$11.50, consensus $11.39 02/02/23 Air Products sees Q2 adjusted EPS $2.50-$2.70, consensus $2.68 02/02/23 Air Products reports Q1 adjusted EPS $2.64, consensus $2.70 11/03/22 Air Products sees FY23 EPS $11.20-$11.50, consensus $11.37 05/12/23 Annual Growth Discovery Virtual Conference
Technical Analysis	NASDAQ market internals summary » 13:17 03/27/23 03/27 13:17 03/27/23 13:17 $NSD NASDAQ Market Internals / + Volume is above average… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Technical Analysis $NSD NASDAQ Market Internals / + 12:17 Today NASDAQ market internals summary 11:17 Today NASDAQ market internals summary 10:17 Today NASDAQ market internals summary 03/24/23 NASDAQ market internals summary
Technical Analysis	NYSE market internals summary » 13:16 03/27/23 03/27 13:16 03/27/23 13:16 $NYE NYSE Market Internals / + Volume is average for… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Technical Analysis $NYE NYSE Market Internals / + 11:16 Today NYSE market internals summary 10:16 Today NYSE market internals summary 03/24/23 NYSE market internals summary 03/24/23 NYSE market internals summary
Earnings	Notable companies reporting before tomorrow's open » 13:13 03/27/23 03/27 13:13 03/27/23 13:13 WBA Walgreens Boots Alliance $33.10 / +0.4 (+1.22%) Notable companies… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options WBA Walgreens Boots Alliance $33.10 / +0.4 (+1.22%) 03/14/23 Senate Democrats urge Walmart, Kroger, others to sell mifepristone 03/06/23 Walgreens Boots Alliance to dispense Mifepristone where 'legally permissible' 03/06/23 California 'done' with Walgreens over abortion pill stance 03/02/23 Walgreens with DoorDash, Uber announce free Same Day Rx Delivery for HIV WBA Walgreens Boots Alliance $33.10 / +0.4 (+1.22%) 03/26/23 Barclays Walgreens Boots Alliance price target lowered to $43 from $45 at Barclays 03/22/23 Evercore ISI Walgreens Boots Alliance price target lowered to $35 from $36 at Evercore ISI 02/23/23 Loop Capital Loop Capital starts Walgreens Boots at Buy, sees higher growth from healthcare 02/22/23 Loop Capital Walgreens Boots Alliance initiated with a Buy at Loop Capital WBA Walgreens Boots Alliance $33.10 / +0.4 (+1.22%) 01/05/23 Walgreens Boots Alliance backs FY23 adjusted EPS view $4.45-$4.65 01/05/23 Walgreens Boots Alliance reports Q1 adjusted EPS $1.16, consensus $1.13 01/04/23 Notable companies reporting before tomorrow's open 01/04/23 Notable companies reporting before tomorrow's open WBA Walgreens Boots Alliance $33.10 / +0.4 (+1.22%) 03/08/23 Walgreens stops offer abortion pill in 21 states, face blowback, NYTimes report 03/03/23 Walgreens will not distribute abortion pills in 20 states, Reuters report 01/25/23 Walgreens weighing sale of $2B pharmacy automation business, Bloomberg says 01/19/23 Rite Aid plans to provide abortion pill in some stores, Bloomberg reports WBA Walgreens Boots Alliance $33.10 / +0.4 (+1.22%) 03/06/23 What You Missed On Wall Street On Monday 02/25/23 Buy/Sell: Wall Street's top 10 stock calls this week 02/23/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 01/25/23 What You Missed On Wall Street On Wednesday 03/28/23 Walgreens Boots Alliance - WBA WBA Walgreens Boots Alliance $33.10 / +0.4 (+1.22%) 09:40 Today Unusually active option classes on open March 27th 03/13/23 Walgreen Boots call volume above normal and directionally bullish 01/05/23 Unusually active option classes on open January 5th 11/11/22 Unusually active option classes on open November 11th
General news	2-year note auction » 13:09 03/27/23 03/27 13:09 03/27/23 13:09 $ECON Economic Data / + Total Amount: $42B, Rate:… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Periodicals On The Fly Technical Analysis $ECON Economic Data / + 03/22/23 Senators Scott, Warren unveil bipartisan Fed oversight legislation 03/01/23 Einhorn says investors should be 'bearish on stocks and bullish on inflation' $ECON Economic Data / + $ECON Economic Data / + 03/08/23 Biden to propose 25% billionaire tax, Bloomberg says 03/08/23 Biden to propose 25% billionaire tax, Bloomberg says 03/07/23 Powell tells Congress data from January partly reversed softening trends 01/30/23 Fed likely to raise funds rate benchmark by quarter percentage point, WSJ says $ECON Economic Data / + 03/22/23 What You Missed On Wall Street On Wednesday 03/21/23 What You Missed On Wall Street On Tuesday 03/21/23 What You Missed On Wall Street This Morning 03/08/23 What You Missed On Wall Street On Wednesday $ECON Economic Data / + 03/22/23 Fed says 'additional policy firming may be appropriate'
Hot Stocks	Nano Dimension files lawsuit against Murchinson, Anson and Boothbay » 13:08 03/27/23 03/27 13:08 03/27/23 13:08 NNDM Nano Dimension $2.60 / +0.01 (+0.39%) Nano Dimension has filed… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options NNDM Nano Dimension $2.60 / +0.01 (+0.39%) 10:06 Today Nano Dimension announces purchase order from Fraunhofer Institue 03/23/23 Nano Dimension to review options relative to Stratasys and alternative targets 03/23/23 Nano Dimension releases video on products, materials, technologies 03/22/23 Stratasys board unanimously rejects acquisition proposal from Nano Dimension NNDM Nano Dimension $2.60 / +0.01 (+0.39%) 03/10/23 Lake Street Nano Dimension made 'lowball offer' Stratasys won't accept, says Lake Street NNDM Nano Dimension $2.60 / +0.01 (+0.39%) 01/24/23 Nano Dimension reports Q4 revenue $12.1M, up 61% vs. 4Q21 12/01/22 Nano Dimension reports Q3 EPS (26c) vs. (7c) last year 10/24/22 Nano Dimension sees Q3 revenue $10M NNDM Nano Dimension $2.60 / +0.01 (+0.39%) 03/07/23 Nano Dimension receives purchase order for DragonFly IV system NNDM Nano Dimension $2.60 / +0.01 (+0.39%) 03/24/23 What You Missed On Wall Street On Friday 03/24/23 What You Missed On Wall Street This Morning 03/20/23 Fly Intel: After-Hours Movers 03/14/23 What You Missed On Wall Street On Tuesday 03/30/23 Nano Dimension - NNDM NNDM Nano Dimension $2.60 / +0.01 (+0.39%) 03/07/23 Unusually active option classes on open March 7th 01/20/23 Largest borrow rate increases among liquid names

Upgrade	Novartis upgraded to Hold at Deutsche Bank after Kisqali's 'positive surprise' » 13:07 03/27/23 03/27 13:07 03/27/23 13:07 NVS Novartis $90.14 / +6.555 (+7.84%) Deutsche Bank upgraded… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options NVS Novartis $90.14 / +6.555 (+7.84%) 12:00 Today Novartis rises 7.5% 06:46 Today Novartis says Kisqali Phase 3 NATALEE trial met primary endpoint at interim 03/24/23 23andMe pilots program to raise awareness about Lipoprotein(a) 03/21/23 Novartis alpelisib granted FDA orphan designation NVS Novartis $90.14 / +6.555 (+7.84%) 12:59 Today Deutsche Bank Novartis upgraded to Hold from Sell at Deutsche Bank 07:24 Today BofA Novartis' NATALEE readout a 'best case scenario,' says BofA 07:18 Today Morgan Stanley Morgan Stanley expects Novartis to outperform after Kisqali 'positive surprise' 01/26/23 Citi Novartis downgraded to Neutral from Buy at Citi NVS Novartis $90.14 / +6.555 (+7.84%) 02/01/23 Novartis sees core operating income to grow mid single digit percentage in 2023 02/01/23 Novartis reports Q4 core EPS $1.52, consensus $1.44 10/25/22 Novartis confirms mid single digit sales, core operating income guidance 10/25/22 Novartis reports Q3 core EPS $1.58 vs. $1.71 last year NVS Novartis $90.14 / +6.555 (+7.84%) 03/22/23 Novartis halts Leqvio heart attack prevention trial, Reuters reports 02/08/23 Avrobio exploring potential sale after approach, Street Insider says 12/29/22 Novartis to pay $245M to settle lawsuit on Exforge medicine, Bloomberg reports 11/16/22 Novartis exploring sale of ophthalmology, respiratory units, Bloomberg says NVS Novartis $90.14 / +6.555 (+7.84%) 03/22/23 What You Missed On Wall Street On Wednesday 03/22/23 What You Missed On Wall Street This Morning 02/10/23 Biotech Alert: Searches spiking for these stocks today 02/01/23 What You Missed On Wall Street This Morning NVS Novartis $90.14 / +6.555 (+7.84%) 01/09/23 Novartis call volume above normal and directionally bullish 12/16/22 Novartis call volume above normal and directionally bullish 10/06/22 Novartis put volume heavy and directionally bearish
Conference/Events	Compass Pathways management to meet virtually with Cantor Fitzgerald » 13:06 03/27/23 03/27 13:06 03/27/23 13:06 CMPS Compass Pathways $10.28 / +0.26 (+2.59%) Virtual Meetings to be… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events CMPS Compass Pathways $10.28 / +0.26 (+2.59%) 02/28/23 Compass Pathways sees 2023 net cash use $85M-$110M 01/26/23 Cathie Wood's ARK Investment bought 120.3K shares of Compass Pathways today 01/19/23 Cathie Wood's ARK Investment bought 158.2K shares of Compass Pathways today 01/18/23 Cathie Wood's ARK Investment bought 156.6K shares of Compass Pathways today CMPS Compass Pathways $10.28 / +0.26 (+2.59%) 01/09/23 Loop Capital Atai Life Sciences price target lowered to $10 from $18 at Loop Capital 12/15/22 EF Hutton Compass Pathways initiated with a Buy at EF Hutton 12/09/22 Oppenheimer Compass Pathways price target lowered to $33 from $55 at Oppenheimer 11/01/22 Loop Capital Compass Pathways initiated with a Buy at Loop Capital CMPS Compass Pathways $10.28 / +0.26 (+2.59%) 02/28/23 Compass Pathways reports Q4 EPS (73c), consensus (59c) 11/03/22 Compass Pathways reports Q3 EPS (43c), consensus (65c) CMPS Compass Pathways $10.28 / +0.26 (+2.59%) 01/03/23 Oregon becomes first U.S. state to legalize 'magic' mushrooms, NYT says CMPS Compass Pathways $10.28 / +0.26 (+2.59%) 03/23/23 Here's What You Missed in Cannabis, Psychedelics This Week 03/16/23 Rising High: Exclusive talk with house of brands Carma HoldCo 03/09/23 Rising High: Exclusive talk with cannabinoid market research firm BDSA 03/02/23 Rising High: Exclusive talk with vertically-integrated MSO Greenlight 03/29/23 Compass Pathways 03/30/23 Compass Pathways
Options	PVH Corp. options imply 5.1% move in share price post-earnings » 13:04 03/27/23 03/27 13:04 03/27/23 13:04 PVH PVH Corp. $73.70 / +0.795 (+1.09%) Pre-earnings options… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events PVH PVH Corp. $73.70 / +0.795 (+1.09%) 03/08/23 PVH Corp. names Amber McCann Chief Communications Office 12/01/22 PVH Corp. rises 10.2% 12/01/22 PVH Corp. rises 10.5% 11/30/22 PVH Corp. jumps 9% to $73.38 after Q3 earnings beat, guidance raise PVH PVH Corp. $73.70 / +0.795 (+1.09%) 03/21/23 UBS PVH Corp. price target lowered to $92 from $100 at UBS 03/20/23 Goldman Sachs PVH Corp. price target raised to $74 from $67 at Goldman Sachs 02/15/23 Wells Fargo PVH Corp. price target raised to $110 from $85 at Wells Fargo 01/23/23 JPMorgan PVH Corp. price target raised to $95 from $77 at JPMorgan PVH PVH Corp. $73.70 / +0.795 (+1.09%) 11/30/22 PVH Corp. raises FY22 EPS view to $8.25 from $8, consensus $7.89 11/30/22 PVH Corp. sees Q4 adjusted EPS $1.65, consensus $1.70 11/30/22 PVH Corp. reports Q3 adjusted EPS $2.60, consensus $2.15 11/30/22 Notable companies reporting after market close PVH PVH Corp. $73.70 / +0.795 (+1.09%) 12/01/22 What You Missed On Wall Street On Thursday 12/01/22 What You Missed On Wall Street This Morning 12/01/22 Fly Intel: Pre-market Movers 11/30/22 Fly Intel: After-Hours Movers 03/28/23 PVH Corp. - PVH
Hot Stocks	CN, Trealmont, Kaptan plan for new Calgary intermodal transload facility » 13:02 03/27/23 03/27 13:02 03/27/23 13:02 CNI Canadian National $114.65 / +0.95 (+0.84%) CN, Trealmont Transport… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events CNI Canadian National $114.65 / +0.95 (+0.84%) 03/22/23 North American rail traffic down 6.9% for the week ending March 18 03/20/23 Canadian National, Unifor reach tentative agreements 03/15/23 North American rail traffic down 6.1% for the week ending March 11 03/08/23 North American rail traffic down 4.4% for the week ending March 4 CNI Canadian National $114.65 / +0.95 (+0.84%) 07:12 Today BofA Canadian National price target lowered to $134 from $137 at BofA 01/25/23 Desjardins Canadian National price target lowered to C$179 from C$180 at Desjardins 01/25/23 CIBC Canadian National price target lowered to C$175 from C$181 at CIBC 01/25/23 BMO Capital Canadian National price target lowered to C$180 from C$185 at BMO Capital CNI Canadian National $114.65 / +0.95 (+0.84%) 01/24/23 Canadian National reports Q4 EPS C$2.10, consensus C$2.08 10/25/22 Canadian National raises FY22 adjusted EPS view to up 25% from up 15%-20% 10/25/22 Canadian National reports Q3 adjusted EPS C$2.13 vs. C$2.37 last year CNI Canadian National $114.65 / +0.95 (+0.84%) 03/07/23 Ohio crash highlights gap in federal safety regulations, NY Times reports 03/03/23 Norfolk Southern, railroads to join close-call reporting system, WSJ reports 12/01/22 Senate approves bill to force tentative rail labor agreement, CNBC says 11/30/22 House passes bill to avoid rail strike, NBC News reports CNI Canadian National $114.65 / +0.95 (+0.84%) 01/24/23 Fly Intel: After-Hours Movers 11/30/22 What You Missed On Wall Street On Wednesday 11/29/22 What You Missed On Wall Street On Tuesday 11/29/22 What You Missed On Wall Street This Morning 04/24/23 Canadian National - CNI
Upgrade	Novartis upgraded to Hold from Sell at Deutsche Bank » 12:59 03/27/23 03/27 12:59 03/27/23 12:59 NVS Novartis $90.21 / +6.625 (+7.93%) Deutsche Bank analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options NVS Novartis $90.21 / +6.625 (+7.93%) 12:00 Today Novartis rises 7.5% 06:46 Today Novartis says Kisqali Phase 3 NATALEE trial met primary endpoint at interim 03/24/23 23andMe pilots program to raise awareness about Lipoprotein(a) 03/21/23 Novartis alpelisib granted FDA orphan designation NVS Novartis $90.21 / +6.625 (+7.93%) 07:24 Today BofA Novartis' NATALEE readout a 'best case scenario,' says BofA 07:18 Today Morgan Stanley Morgan Stanley expects Novartis to outperform after Kisqali 'positive surprise' 01/26/23 Citi Novartis downgraded to Neutral from Buy at Citi 01/24/23 Lake Street Harrow Health price target raised to $24 from $17 at Lake Street NVS Novartis $90.21 / +6.625 (+7.93%) 02/01/23 Novartis sees core operating income to grow mid single digit percentage in 2023 02/01/23 Novartis reports Q4 core EPS $1.52, consensus $1.44 10/25/22 Novartis confirms mid single digit sales, core operating income guidance 10/25/22 Novartis reports Q3 core EPS $1.58 vs. $1.71 last year NVS Novartis $90.21 / +6.625 (+7.93%) 03/22/23 Novartis halts Leqvio heart attack prevention trial, Reuters reports 02/08/23 Avrobio exploring potential sale after approach, Street Insider says 12/29/22 Novartis to pay $245M to settle lawsuit on Exforge medicine, Bloomberg reports 11/16/22 Novartis exploring sale of ophthalmology, respiratory units, Bloomberg says NVS Novartis $90.21 / +6.625 (+7.93%) 03/22/23 What You Missed On Wall Street On Wednesday 03/22/23 What You Missed On Wall Street This Morning 02/10/23 Biotech Alert: Searches spiking for these stocks today 02/01/23 What You Missed On Wall Street This Morning NVS Novartis $90.21 / +6.625 (+7.93%) 01/09/23 Novartis call volume above normal and directionally bullish 12/16/22 Novartis call volume above normal and directionally bullish 10/06/22 Novartis put volume heavy and directionally bearish
Hot Stocks	BioMarin granted orphan status for DMD treatment » 12:58 03/27/23 03/27 12:58 03/27/23 12:58 BMRN BioMarin $91.67 / +0.985 (+1.09%) The FDA granted BioMarin… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events BMRN BioMarin $91.67 / +0.985 (+1.09%) 03/07/23 BioMarin: FDA accepts sNDA to expand use of VOXZOGO for injection 03/06/23 BioMarin says FDA extends review of BLA for Roctavian 01/08/23 BioMarin announces data from follow up from Phase 3 GENEr8-1 study of ROCTAVIAN 01/03/23 BioMarin's application for Voxzogo in achondroplasia validated by EMA BMRN BioMarin $91.67 / +0.985 (+1.09%) 03/21/23 Bernstein BioMarin initiated with an Underperform at Bernstein 03/09/23 Chardan Tenaya Therapeutics price target lowered to $24 from $28 at Chardan 02/28/23 Stifel BioMarin price target raised to $118 from $114 at Stifel 02/28/23 Wedbush BioMarin price target lowered to $74 from $83 at Wedbush BMRN BioMarin $91.67 / +0.985 (+1.09%) 02/27/23 BioMarin sees FY23 EPS under new method of $1.80-$2.05, consensus $1.61 02/27/23 BioMarin reports Q4 EPS (0c), consensus (7c) 02/27/23 Notable companies reporting after market close 10/26/22 BioMarin backs FY22 revenue view $2.06B-$2.16B, consensus $2.12B BMRN BioMarin $91.67 / +0.985 (+1.09%) 03/24/23 Buy/Sell: Wall Street's top 10 stock calls this week 03/21/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/22/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/21/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/30/23 PDUFA Date for Roctavian--Extended 10/21/23 PDUFA Date for VOXZOGO
Hot Stocks	Incyte granted orphan status for myelofibrosis treatment » 12:57 03/27/23 03/27 12:57 03/27/23 12:57 INCY Incyte $70.82 / +0.59 (+0.84%) The FDA granted Incyte… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options INCY Incyte $70.82 / +0.59 (+0.84%) 05:20 Today Incyte announces Japanese MHLW approval of Pemazyre 03/23/23 Incyte provides regulatory update on Ruxolitinib extended relief 03/22/23 MacroGenics to receive $15M milestone following FDA approval of Zynyz 03/22/23 Incyte announces FDA accelerated approval of Zynyz INCY Incyte $70.82 / +0.59 (+0.84%) 03/24/23 SVB Securities Incyte upgraded to Market Perform at SVB after ruxolitinib XR CRL, Zynz approval 03/24/23 SVB Securities Incyte upgraded to Market Perform from Underperform at SVB Securities 03/24/23 BofA BofA sees minimal near-term impact on Incyte from ruxolitinib ER CRL 02/08/23 Cowen Incyte price target raised to $100 from $95 at Cowen INCY Incyte $70.82 / +0.59 (+0.84%) 02/07/23 Incyte reports Q4 EPS 62c, consensus 58c 02/06/23 Notable companies reporting before tomorrow's open 02/06/23 Notable companies reporting before tomorrow's open 11/01/22 Incyte reports Q3 EPS 60c, consensus 72c INCY Incyte $70.82 / +0.59 (+0.84%) 01/31/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/10/23 Incyte 04/11/23 Incyte INCY Incyte $70.82 / +0.59 (+0.84%) 11/01/22 Early notable gainers among liquid option names on November 1st
Hot Stocks	Centene appoints Tanya McNally as Chief People Officer » 12:49 03/27/23 03/27 12:49 03/27/23 12:49 CNC Centene $64.58 / +0.545 (+0.85%) Centene announced the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options CNC Centene $64.58 / +0.545 (+0.85%) 02/08/23 California AG announces $215M settlement against Centene 02/02/23 Managed care stocks pressured after CMS' preliminary Medicare Advantage rates 01/23/23 Centene completes divestiture of Magellan Specialty Health to Evolent Health 01/03/23 Centene's Health Net selected for new medi-cal direct contracts CNC Centene $64.58 / +0.545 (+0.85%) 03/21/23 Wells Fargo Molina Healthcare price target lowered to $282 from $307 at Wells Fargo 03/21/23 Wells Fargo Centene price target lowered to $71 from $79 at Wells Fargo 03/08/23 Deutsche Bank Centene downgraded to Hold on estimate risk at Deutsche Bank 03/08/23 Deutsche Bank Centene downgraded to Hold from Buy at Deutsche Bank CNC Centene $64.58 / +0.545 (+0.85%) 02/07/23 Centene backs FY23 adjusted EPS view $6.25-$6.40, consensus $6.36 02/07/23 Centene reports Q4 EPS 86c, consensus 85c 02/06/23 Notable companies reporting before tomorrow's open 02/06/23 Notable companies reporting before tomorrow's open CNC Centene $64.58 / +0.545 (+0.85%) 11/29/22 Managed care company returns will be tough to keep replicating, WSJ says CNC Centene $64.58 / +0.545 (+0.85%) 03/08/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/23/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 01/03/23 What You Missed On Wall Street On Tuesday 01/03/23 What You Missed On Wall Street This Morning 04/25/23 Centene - CNC 05/10/23 Centene Corp. CNC Centene $64.58 / +0.545 (+0.85%) 01/17/23 Centene call volume above normal and directionally bullish 01/09/23 Centene put volume heavy and directionally bearish 12/22/22 Early notable gainers among liquid option names on December 22nd 11/21/22 Centene put volume heavy and directionally bearish
Hot Stocks	Kludein I Acquisition Corp trading resumes 12:43 03/27/23 03/27 12:43 03/27/23 12:43 NIR Near Intelligence $6.20 / -6.15 (-49.80%) ShowHide Related Items >><< Company News NIR Near Intelligence $6.20 / -6.15 (-49.80%) 12:38 Today Kludein I Acquisition Corp trading halted, volatility trading pause 03/23/23 Near Intelligence completes business combination, to trade on Nasdaq
Conference/Events	Payoneer Global management to meet with Cantor Fitzgerald » 12:40 03/27/23 03/27 12:40 03/27/23 12:40 PAYO Payoneer Global $6.06 / +0.015 (+0.25%) Group luncheon meeting… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options PAYO Payoneer Global $6.06 / +0.015 (+0.25%) 03/10/23 Payoneer says less than $20M of cash balances held at SVB 02/28/23 Payoneer Global appoints John Caplan as CEO, effective March 1 02/17/23 Payoneer Global receives UK E-Money license from Financial Conduct Authority 01/18/23 Payoneer appoints Ordonez as deputy CFO PAYO Payoneer Global $6.06 / +0.015 (+0.25%) 02/27/23 Jefferies Payoneer Global initiated with a Buy at Jefferies 01/11/23 Wolfe Research Payoneer Global initiated with an Outperform at Wolfe Research 12/30/22 Northland Payoneer Global named a top pick for 2023 at Northland 11/10/22 Citi Payoneer Global price target raised to $10 from $9 at Citi PAYO Payoneer Global $6.06 / +0.015 (+0.25%) 02/28/23 Payoneer Global sees FY23 revenue $800M-$810M, consensus $738.4M 02/28/23 Payoneer Global reports Q4 EPS (3c), consensus (5c) 11/09/22 Payoneer Global sees FY22 revenue $605M-$615M, consensus $598.11M 11/09/22 Payoneer Global reports Q3 EPS (8c), consensus (2c) PAYO Payoneer Global $6.06 / +0.015 (+0.25%) 02/28/23 Fly Intel: After-Hours Movers 10/10/22 What You Missed On Wall Street On Monday 10/10/22 What You Missed On Wall Street This Morning 10/07/22 What You Missed On Wall Street On Friday 03/29/23 Payoneer Global PAYO Payoneer Global $6.06 / +0.015 (+0.25%) 11/16/22 Payoneer Global call volume above normal and directionally bullish

Hot Stocks	Kludein I Acquisition Corp trading halted, volatility trading pause 12:38 03/27/23 03/27 12:38 03/27/23 12:38 NIR Near Intelligence $6.20 / -6.15 (-49.80%) ShowHide Related Items >><< Company News NIR Near Intelligence $6.20 / -6.15 (-49.80%) 03/23/23 Near Intelligence completes business combination, to trade on Nasdaq
Downgrade	Jounce Therapeutics downgraded to Neutral from Overweight at Piper Sandler » 12:37 03/27/23 03/27 12:37 03/27/23 12:37 JNCE Jounce Therapeutics $1.86 / +0.35 (+23.26%) Piper Sandler analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly JNCE Jounce Therapeutics $1.86 / +0.35 (+23.26%) 09:50 Today Jounce Therapeutics trading resumes 09:04 Today Jounce Therapeutics implements workforce reduction of 84% of employees 09:03 Today Jounce to be acquired by Concentra for $1.85 in cash per share plus CVR 08:55 Today Jounce Therapeutics trading halted, news pending JNCE Jounce Therapeutics $1.86 / +0.35 (+23.26%) 02/24/23 SMBC Nikko Jounce Therapeutics downgraded to Neutral from Outperform at SMBC Nikko 02/23/23 Raymond James Jounce downgraded to Market Perform from Outperform at Raymond James 01/02/23 Piper Sandler Piper Sandler keeps Overweight on Jounce Therapeutics, lowers price target to $5 11/11/22 Raymond James Raymond James downgrades Jounce to Outperform on ILT inhibitor data JNCE Jounce Therapeutics $1.86 / +0.35 (+23.26%) 11/10/22 Jounce Therapeutics reports Q3 EPS (60c), consensus (64c) JNCE Jounce Therapeutics $1.86 / +0.35 (+23.26%) 12:04 Today What You Missed On Wall Street This Morning 03/16/23 Biotech Alert: Searches spiking for these stocks today 12/30/22 Biotech Alert: Searches spiking for these stocks today 12/28/22 What You Missed On Wall Street On Wednesday
Conference/Events	Haynes management to meet virtually with Benchmark » 12:25 03/27/23 03/27 12:25 03/27/23 12:25 HAYN Haynes $48.55 / +1.05 (+2.21%) Virtual Meeting to be… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research Earnings On The Fly Events HAYN Haynes $48.55 / +1.05 (+2.21%) 02/16/23 Noble Capital Haynes initiated with an Outperform at Noble Capital 11/15/22 KeyBanc Haynes downgraded to Sector Weight from Overweight at KeyBanc 07/08/22 KeyBanc KeyBanc cuts price targets on aerospace materials sub-sector 04/01/22 KeyBanc Haynes price target raised to $55 from $41 at KeyBanc HAYN Haynes $48.55 / +1.05 (+2.21%) 02/02/23 Haynes reports Q1 EPS 67c, consensus 66c 11/17/22 Haynes sees Q1 EPS 55c-70c, consensus 96c 11/17/22 Haynes reports Q4 EPS $1.30, consensus $1.28 HAYN Haynes $48.55 / +1.05 (+2.21%) 02/16/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 13:00 Today Haynes
Recommendations	JPMorgan strategist says Q1 likely high point for equities this year » 12:24 03/27/23 03/27 12:24 03/27/23 12:24 $ECON Economic Data / + , SPX S&P 500 / + , SPY SPDR S&P 500 ETF Trust $395.73 / +0.005 (+0.00%) JPMorgan's Global… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Periodicals On The Fly Options Technical Analysis $ECON SPX SPY $ECON Economic Data / + 03/22/23 Senators Scott, Warren unveil bipartisan Fed oversight legislation 03/01/23 Einhorn says investors should be 'bearish on stocks and bullish on inflation' SPX S&P 500 / + 03/22/23 Senators Scott, Warren unveil bipartisan Fed oversight legislation 03/01/23 Einhorn says not invested long in artificial intelligence companies 03/01/23 Einhorn says investors should be 'bearish on stocks and bullish on inflation' 12/14/22 SEC proposes rules to enhance competition for retail order flow execution SPY SPDR S&P 500 ETF Trust $395.73 / +0.005 (+0.00%) 03/22/23 Senators Scott, Warren unveil bipartisan Fed oversight legislation 03/01/23 Einhorn says not invested long in artificial intelligence companies 03/01/23 Einhorn says investors should be 'bearish on stocks and bullish on inflation' 12/14/22 SEC proposes rules to enhance competition for retail order flow execution $ECON SPX SPY $ECON Economic Data / + SPX S&P 500 / + SPY SPDR S&P 500 ETF Trust $395.73 / +0.005 (+0.00%) $ECON SPX SPY $ECON Economic Data / + 03/08/23 Biden to propose 25% billionaire tax, Bloomberg says 03/08/23 Biden to propose 25% billionaire tax, Bloomberg says 03/07/23 Powell tells Congress data from January partly reversed softening trends 01/30/23 Fed likely to raise funds rate benchmark by quarter percentage point, WSJ says SPX S&P 500 / + 03/20/23 Treasury considering expanding FDIC coverage to all deposits, Bloomberg reports 03/14/23 Fed may extend tougher capital restrictions to midsize banks, WSJ says 03/08/23 Biden to propose 25% billionaire tax, Bloomberg says 03/08/23 Biden to propose 25% billionaire tax, Bloomberg says SPY SPDR S&P 500 ETF Trust $395.73 / +0.005 (+0.00%) 03/20/23 Treasury considering expanding FDIC coverage to all deposits, Bloomberg reports 03/14/23 Fed may extend tougher capital restrictions to midsize banks, WSJ says 03/08/23 Biden to propose 25% billionaire tax, Bloomberg says 03/08/23 Biden to propose 25% billionaire tax, Bloomberg says $ECON SPX SPY $ECON Economic Data / + 03/22/23 What You Missed On Wall Street On Wednesday 03/21/23 What You Missed On Wall Street On Tuesday 03/21/23 What You Missed On Wall Street This Morning 03/08/23 What You Missed On Wall Street On Wednesday SPX S&P 500 / + 03/22/23 What You Missed On Wall Street On Wednesday 03/21/23 What You Missed On Wall Street On Tuesday 03/21/23 What You Missed On Wall Street This Morning 03/17/23 What You Missed On Wall Street On Friday SPY SPDR S&P 500 ETF Trust $395.73 / +0.005 (+0.00%) 03/22/23 What You Missed On Wall Street On Wednesday 03/21/23 What You Missed On Wall Street On Tuesday 03/17/23 What You Missed On Wall Street On Friday 03/08/23 What You Missed On Wall Street On Wednesday SPX SPX S&P 500 / + 03/24/23 SPX options flow afternoon update $ECON SPX SPY $ECON Economic Data / + 03/22/23 Fed says 'additional policy firming may be appropriate' SPX S&P 500 / + 03/22/23 Fed says 'additional policy firming may be appropriate' SPY SPDR S&P 500 ETF Trust $395.73 / +0.005 (+0.00%) 08:24 Today SPDR S&P 500 ETF Trust: Pivot points 03/24/23 SPDR S&P 500 ETF Trust: Pivot points 03/23/23 SPDR S&P 500 ETF Trust: Pivot points 03/22/23 Fed says 'additional policy firming may be appropriate'
Recommendations	Vislink price target lowered to $1 from $1.25 at Alliance Global Partners » 12:19 03/27/23 03/27 12:19 03/27/23 12:19 VISL Vislink / + Alliance Global Partners… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events VISL Vislink / + 01/04/23 Vislink receives over $2M in new airborne downlink orders from U.S., Canada VISL Vislink / + 11/15/22 Alliance Global Partners Vislink price target lowered to $1.25 from $1.75 at Alliance Global Partners VISL Vislink / + 07:34 Today Vislink reports preliminary FY22 EPS (29c) vs (38c) last year 08:30 Today Vislink - VISL